Guarantees of Origin (GOs) are the most efficient ways to source renewable energy. However, the market can be volatile and opaque. Our aim is to simplify this complex market to make informed decisions. As the forefront company for Green Certificates market intelligence, Greenfact supports over 300 firms by providing price benchmarking, insights, and analytics for Green Certificates in the Nordics and Europe.

Niuton is a deep tech platform that works on autonomous and decentralized solutions based on Newtonian principles and our end customers are hedge funds. Currently, we have a team of five people, the tech dev and research stretches three years back and we have been with one year live with clients. Now we are looking for a senior python specialist to automate the data flow in and out of our core machinery. The data feed into Niutons machinery is from Twelvedata and the output is clients around the world. For the right candidate, we can consider offering 0.5% of shares equity (valuation right now 7.5 million USD), you will be assisted by our other senior python specialist that handles the core machinery itself. The expected duration of this assignment is three to four months ONLY. Start date 1. January 2022. Resources have to be available 100% of the time during the assignment, most preferably in Oslo. The MVP is ready, Niuton is now exactly what we want, and the success criterion is achieving 99% uptime on a day-to-day basis.

We enable the green shift to happen in new markets! TioTech is a Norwegian producer of titania (TiO2) nanomaterials and a developer of titania-based technology. We know how to optimise the production process and properties of titania nanoparticles. After successfully developing and commercialising a series of photocatalytic surface treatment products (www.joma-int.com), we are directing our R&D efforts towards a new area; the use of titania as anode-material in Lithium-ion batteries (LIB). A battery with our material on the anode will charge faster, last longer, be safer and tolerate temperature variation better than conventional batteries which have graphite on the anode, and outcompete LTO-batteries on capacity. The development work takes place in our in-house laboratory in Bergen, where our dedicated team (Hjørdis, Marthe, Rob, Anders) play around with titania, giving life to innovative solutions.

Humans for Humans is a non-governmental organization that provides free mental health support for human trafficking survivors, those indirectly affected by human trafficking, and the professionals who work with them. Moreover, we aim to promote the anti-trafficking movement and contribute to the awareness and eradication of modern slavery.

Hva er Crescat?Crescat er systemet som hjelper deg med planlegging og gjennomføring av arrangementer. Samarbeid enkelt med alle, i ett og samme system. Crescat er utviklet i tett samarbeid med kulturbransjen. Våre kunder er arrangører, eventbyrå, scener og kulturhus. Vi jobber for å gjøre kundens hverdag enklere. Hvem er vi?Crescat er gründerbedrift i vekst, med utspring i Bergen. Vi holder til midt i Bergen sentrum i topp moderne lokaler. Crescat-teamet består idag av et knippe inspirerte og hardtarbeidende mennesker. Vi har et ungt og dynamisk miljø, og vi har et sterkt fokus på at alle skal trives og ha det gøy på jobb.

Founded in 2018 by Bård Anders and Stig Olav Kasin, PortalOne is the world’s first hybrid games platform. Hybrid games are a new category of entertainment that seamlessly mix games with live shows that are embedded directly inside the games. This mobile-first content gives users a more engaging games experience, with stunning visuals and enhanced interactivity while allowing users to compete for prizes. We enrich everyday life by providing captivating, positive entertainment — with rewarding interactions that transform virtual wins into real-world rewards. PortalOne is US-based with a subsidiary in Oslo, Norway Hybrid Games are a whole new category of unique gaming entertainment. We harness the power of the Unreal Engine and other technologies to create unique content with stunning visuals and interactivity.We have global financial backing and global partners.

Disruptive Engineering enables more effective planning, management, and monitoring of road networks. Proprietary sensor hardware 'made in Norway'Use AI and neural networks for detailed classification of vehicles. Privacy-by-design solution ensuring that no personal data is stored or shared. With traffic expected to grow by 60% by 2050, and with congestion and safety already being an issue, there is a pressing need to utilize road networks more efficiently. Both Statens Vegvesen and Nye Veier see our first sensor VS1, and the valuable data it provides, as a potential solution to achieve this as well as an opportunity to digitalize roads and infrastructure for the forthcoming Intelligent Transportation Systems (ITS) that are being implemented across Europe.Statens Vegvesen linkNye Veier link

UpNorth Ventures was formed in 2017 by a team of experienced entrepreneurs/executives with broad business, financial, tech and entrepreneurial backgrounds. The team is supported by a network of tech resources and other. We are growing, and currently looking for new partners and employees. We believe in building companies from scratch with a bootstrap mentality that makes them profitable early on. Are you an entrepreneur, investor or just curious, then let us know at hello@upnorth.vc

People find going to the optician frustrating and it is something they tend to delay as long as possible. Pain points include complicated, non-transparent pricing, lack of understanding about lenses and the options available, and insecurity when choosing glasses. Our mission is to remove these pain points and provide a more relevant modern alternative to the traditional optician. Our vertical concept allows us to offer high-quality designer eyewear at affordable prices - enabling people to build a collection of eyewear to meet the needs of their individual lifestyles. We are currently generating 14 million Nok in sales per year through our 5 Kaibosh stores (Oslo, Bergen, Copenhagen, Frederiksberg & Aarhus), e-commerce operation, and wholesale distribution channels.

Agri-e produces Electricity, heat, Hydrogen, and concentrated CO2 from biogas. Increase biogas value, and increase Food production by use of green concentrated CO2 in a greenhouse, Al has done this in a sustainable way by use of biogas produced from different biological waste streams considered a problem today. Decentralized and scalable energy production to relieve peak stress in el-grid. We are contributing to solving our generation's biggest issue: Producing food and energy in a sustainable green way

Modern, nobel-prize winning research shows that hardly any traditional investment funds are adding any value beyond what fully automated strategies can do. NorQuant's mission is to help private and professional investors achieve higher returns at lower costs through a scientific, rules-based, 100% transparent approach. We feel we are off to a good start: - We are helping our first pilot customer, one of Norway's largest family offices, implement factor-based analysis - We have been selected as one of ten fintech-startups for TheFactory.no Fall18 program, out of more than 200 applications

The job search agent that works for you.

Secure Payment Transaction System with #1 Ranking Our App is integrated with the most secure payment gateways in the world. We use the most advanced encryption technology to ensure that your payment is safe and secure. We are the first to integrate local banks directly with < 1% transaction fee thanks to PSD2 License ( Card-Less Transactional Handshake )

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

AURA Biopharm AS was founded in 2016 by a team of scientists and drug developers with many years of experience in academia and major pharmaceutical companies and a proven track record of success in drug development. The emphasis of AURA is the development of novel and breakthrough therapies for unmet medical needs and orphan diseases and our slogan “A new opportunity for health” reflects AURA's mission to give a new opportunity to diseases in need of new and/or better therapies. The company operates virtually using a network of external collaborators (consultants, KOLs, CROs, CMOs etc).